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Abstract. In the human male, testosterone is the major circulating androgen. The clinical effects of
androgen are numerous, and testosterone deficiency is associated with a number of clinical abnormalities.
At present, a variety of preparations containing testosterone is available for the treatment of androgen
deficiency. Ideally, those treatments have to produce and maintain physiologic serum concentrations of
the hormone. This article reviews the current existing testosterone dosage forms on the market with their
advantages and drawbacks and examines new and emerging technology developments concerning this
therapy. In particular, the latest innovations in transdermal delivery are explored.
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TESTOSTERONE: PRODUCTION
AND DEFICIENCY (1)
Testosterone (17b-hydroxyandrost-4-en-3-one, MW 288)
(Fig. 1) is the principal androgen synthesized in the testis, the
ovary, and the adrenal cortex. This hormone plays an
essential role in the development of the normal male and in
the maintenance of many male characteristics, including
muscle mass and strength, bone mass, libido, potency, and
spermatogenesis. In women, testosterone is thought to
influence pubertal development, sexual function, bone den-
sity, muscle mass, erythropoiesis, energy, cognitive function,
and mood.
Cholesterol is the basic precursor that is transformed
into pregnenolone and then via a variety of progestogens to
androstenedione. This weak androgen is then reduced via
17b-hydroxysteroid oxydoreductase to testosterone (Fig. 2).
Biosynthesis takes place within the Leydig cells of the testis,
stimulated by luteinizing hormone (LH). Ninety-eight per-
cent of circulating testosterone is bound to albumin and sex
hormone binding globulin (SHBG), leaving a small physio-
logically active free fraction.
In the human male, testosterone is the major circulating
androgen. More than 95% of circulating testosterone is
secreted by the testis, with a production rate of 6Y7 mg per
day (2). Circadian (i.e., almost daily) profiles of healthy young
men are characterized by maximum levels of õ25 nmol/L
(720 ng/dL) occurring in the morning (around 0800 hours)
and minimum levels of õ15 nmol/L (430 ng/dL) occurring at
night (around 2200 hours) (3) (Fig. 3). In the peripheral
tissues (including skin and adipose tissue), circulating testos-
terone is enzymatically converted by 5a-reductase and aro-
matase into its active metabolites, dehydrotestosterone
(DHT) and estradiol (E2), respectively (Fig. 2). In normal
men, the resulting plasma levels ratios of DHT/testosterone
and E2/testosterone are õ1:10 and 1:200, respectively.
In women, only small amounts of testosterone are
synthesized in the ovary and adrenal. Healthy premeno-
pausal women produce approximately 300 mg of testosterone
per day, about 5% of the daily production in men (3).
Roughly half of the testosterone produced in women is
derived from the ovaries, the other half from the adrenal
glands, including the peripheral conversion of androgen
precursors, androstenedione and dehydroepiandrosterone
(DHEA), that are secreted from both organs (4). A significant
cycling of androstenedione and testosterone in regularly
ovulating women has been shown, with increases in the
mid-third of the menstrual cycle and a subsequent rise in
androstenedione in the late luteal phase.
Androgen deficiency, also known as hypogonadism
(with testosterone levels less than 7.0 nmol/L or 200 ng/dL)
(5), results from the subnormal production of testosterone by
the testis. Testicular failure (primary hypogonadism) may
have a genetic or a developmental basis or may be acquired.
Hypogonadotropic (secondary) hypogonadism may result
from either acquired or congenital defects in pituitary or
hypothalamic function (Table I).
The clinical manifestations of androgen deficiency de-
pend on the age at onset and the severity and duration of the
deficiency. In adult males, these manifestations may include
reduced body hair, decreased muscle mass and strength,
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increased fat mass and alterations in the distribution of
fat, increased LDL and reduced HDL with risk of heart
disease, decreased hematocrit, decreased libido, erectile dys-
function, infertility, osteoporosis, and depressed mood (6). It
is now appreciated that hypogonadism may also accompany
severe systemic illnesses such as cancer and AIDS (7) and
that transient hypogonadism is frequently associated with
profound emotional and physical stress, as occurs in response
to surgery and burns. In case of androgen deficiency in early
childhood, eunuchoidal proportions, lack of voice mutation,
female distribution of secondary hair, anemia, and underde-
veloped muscles and genitalia can be found, and spermato-
genesis and sexual function are not initiated.
In women, following menopause, there is a drop in the
blood production rate of not only estrogens but also of both
the adrenal and ovarian androgens, namely, DHEA, DHEA
sulfate, androstenedione, and testosterone. Postmenopausal
women produce about 180 mg of testosterone per day. Davis
(8) described a clinical syndrome in women associated with a
relative or absolute deficiency of circulating testosterone
levels. This syndrome, called female androgen deficiency
syndrome (FADS), is characterized by a decreased motiva-
tion or well-being, persistent fatigue, and low libido.
THERAPEUTIC TESTOSTERONE REPLACEMENT
Indications
Testosterone is principally used as a therapeutic agent
for substitutional therapy for climacteric symptoms or for
hypogonadism. It has also been employed to facilitate
development of adult masculine characteristics when the
adolescent process has been delayed (9).
Hypogonadism
Treatment of older men with low testosterone levels has
long been a topic of discussion, but only recently, it became
the object of controlled clinical studies (10). Unlike the
female, in whom reproductive aging culminates in meno-
pause and the cessation of ovarian function, reproductive
aging in the male is a gradual process. There is a slow but
continuous decline in average serum testosterone starting at
20 Y30 years (11). It has been estimated that approximately
50% of healthy men between the ages of 50 and 70 years
have levels of bioavailable testosterone lower than the
normal limit for men aged 20 Y 40 years (12). This decrease
occurs earlier and is more pronounced for free testosterone
levels, decreasing from a mean value of about 0.5 nmol/L in
young adults to approximately 0.2 nmol/L at the age of 80
(13). Whereas younger men have higher serum testosterone
Fig. 1. Structure of testosterone.
Fig. 2. Steroid biosynthesis.
1118 Leichtnam, Rolland, Wu¨thrich, and Guy
levels in the mornings than in the evenings, this circadian
rhythm is often lost in older men (14). There is still some
controversy about hypogonadism being related to aging, but
its incidence does indeed increase with age. Although there is
no indication for testosterone medication in senescent men in
general, when clinical symptoms require it, hypogonadal
older patients should not be denied hormonal substitution.
Efforts are being made to find the appropriate treatment
regimen for such patients (5).
Testosterone replacement in hypogonadal men, both
young and elderly, resulted in an increase in lean body mass,
decrease in fat mass, improvement in sexual function and
quality of life, and increase in bone mineral density (15Y18).
Sexual dysfunction is one of the most common complaints in
men with hypogonadism. This, along with decreased energy,
strength, and mood disorders, results in an overall decrease
in quality of life scores. Therefore, testosterone replacement
is beneficial and is indicated in men with hypogonadism.
Cardiovascular Diseases
Besides these ‘‘classical’’ therapeutic indications, testos-
terone could bring benefit heart and cardiovascular diseases,
too. Until now, masculine hormones were considered delete-
rious for the cardiovascular system. Recent studies have
shown that androgens, used in low doses, could have a
beneficial effect on atherosclerosis and angina pectoris (19).
Alzheimer’s Disease
Recently, it was shown in rats that hyperphosphorylation
of the tau protein, implicated in Alzheimer’s disease, was
prevented by testosterone (20). Thereby, testosterone treat-
ment in old men or testosterone and E2 treatment in
menopausal women may potentially prevent or delay
Alzheimer’s disease. This hypothesis has to be tested in a
clinical study.
Contraception
Another possible clinical application of testosterone is
male contraception. Feedback inhibition of endogenous
synthesis of the hormone is considered to induce infertility,
but the results from clinical trials revealed that only about
60% of the subjects treated with injections of testosterone
esters show azoospermia or oligospermia (21). The objective,
of course, is to totally inhibit spermatogenesis.
Women
Whereas current approaches for treating androgen
deficiency in women are problematic, especially the doses
to be delivered, research is underway to develop new
testosterone delivery systems for women that will provide
sustained physiological levels. Recently, Mazer (22) reviewed
emerging treatments for testosterone deficiency in women.
For women, testosterone therapy may be efficient when
administered with estrogens in the treatment of menopause,
estrogen replacement therapy affecting the total and free
testosterone levels by increasing the levels of LH and SHBG.
Androgens may also have a potential therapeutic role in the
treatment of postmenopausal osteoporosis and fracture
prevention. However, all the currently marketed androgen
preparations are designed for replacement therapy for male
hypogonadism, and although lower doses of testosterone
seem appropriate for use in women, there is currently no
information concerning the most appropriate dose or the
optimal mode or route of testosterone delivery for women.
Marketed Replacement Regimens
A number of therapeutic alternatives are available to the
clinician. The general goal of replacement therapy is to
achieve physiological levels of testosterone (23), with a
minimum of adverse effects and by the most convenient
route of administration. Several options are available for
androgen replacement in adult men, such as oral testoster-
one, intramuscular injections, subcutaneous implants, and
Fig. 3. Circadian variations of testosterone levels in young men (3).
Table I. Low Testosterone Levels: Etiology
Men Women
Congenital hypogonadism Premenopausal
bilateral oophorectomyKlinefelter’s syndrome
(extra X chromosome) Adrenalectomy
GnRH (LHRH) deficiency
(e.g., Kallmann’s syndrome)
Premature ovarian failure
Anorchism Turner’s syndrome
Cryptorchidism Adrenal disease
Acquired hypogonadism Pituitary disease
Chemotherapy HIV infection
Glandular malformation Menopause
Anorchism Oral contraceptives
Head trauma that affects
the hypothalamus
Corticosteroids
Infection (meningitis,
syphilis, mumps)
Oral estrogen products
Isolated LH deficiency
(e.g., fertile eunuch syndrome)
Radiation
Testicular trauma
Tumors of the pituitary gland,
hypothalamus, or testis
Andropause
LH = luteinizing hormone.
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transdermal therapy, each with its unique pharmacokinetic
profile. It is generally agreed that androgen replacement
therapy should deliver physiological amounts (3Y10 mg/day)
of testosterone, produce levels of testosterone, DHT, and E2
within normal physiological ranges, and mimic the circadian
patterns of hormone levels found in healthy young men. It
should have a good safety profile without adverse effects on
the prostate gland, serum lipids, liver, or respiratory function.
Finally, it should be ‘‘patient friendly.’’
Oral Therapy
Although orally administered testosterone is readily
absorbed, it is ineffective because of extensive metabolism
by the liver before reaching the systemic circulation. Thus,
modifications of the testosterone molecule are required to
render it orally active.
A number of different testosterone derivatives have
been used with limited success. Alkylated androgens are
more slowly metabolized than natural testosterone. Like
testosterone, these androgens interact directly with androgen
receptors. 17a-Methyltestosterone and fluoxymesterone both
achieve adequate androgenic effect but with variable clinical
response (24) and unacceptable hepatotoxicity (25). More-
over, alkylated androgens may increase levels of low density
lipoprotein cholesterol and profoundly suppress high density
lipoprotein cholesterol levels because of their route of
absorption and metabolism. Mesterolone, resembling 5a-
dihydrotestosterone, a dihydrotestosterone derivative, seems
safe but lacks androgenic potency (26).
At present, the only recommended orally active andro-
gen is testosterone undecanoate (Fig. 4), formulated as an
oleic acid solution in a soft gelatin capsule (Pantestone\).
This ester is absorbed into the lymphatic system, thereby
avoiding first-pass metabolism. Testosterone undecanoate
administered orally (40 mg, four to four times a day)
produces short-lived peaks of a few hours duration, resulting
in an irregular serum testosterone pattern during the course
of the day. Pharmacokinetics was determined in several
studies and demonstrated high intra- and interindividual
variabilities in serum concentrations (27). For these reasons,
this is not an ideal method of androgen replacement and is
mainly reserved for individuals in whom other methods of
testosterone administration are not successful (28).
Buccal Therapy
The oral mucosal route of administration is well
established for various drugs such as nitroglycerin, which
has been administered sublingually for over 100 years. Oral
mucosal drug delivery offers several advantages over both
injectable and enteral deliveries. Because the oral mucosa is
highly vascularized, absorbed drug directly enters the sys-
temic circulation and avoids low gastric pH, proteases, and
first-pass hepatic degradation (29).
A limitation of oral mucosal delivery is that absorption of
hydrophobic drugs may be more variable than with other
routes. This drawback can be limited using bioadhesive sys-
tems, which can deliver physiologically relevant amounts of
insoluble drugs such as testosterone, as a result of prolonga-
tion of the formulation residence time in the buccal cavity.
Recently, Columbia Laboratories marketed Striant\, a
sustained-release bioadhesive tablet containing 30 mg of
testosterone (30,31). The tablet, which is 9 mm in diameter
and adheres to the patient’s gum, allows the slow release and
absorption of testosterone through gum and cheek surfaces
that are in contact with the tablet. Once applied, the tablet
raises testosterone to normal physiologic levels for 12 h. It is
administered twice daily. This product utilizes both the
bioadhesive delivery system (BDS) and the hydrating buccal
technology platforms previously patented by the company.
Pharmacologically inactive ingredients in Striant\ are anhy-
drous lactose, carbomer 934P, hydroxypropylmethylcellulose,
magnesium stearate, lactose monohydrate, polycarbophil,
colloidal silicon dioxide, starch, and talc.
Intramuscular Therapy
The most commonly employed forms of androgen
replacement therapy are intramuscular depot injections of
the testosterone esters (Fig. 5) in the form of oily suspen-
sions. Esterification increases the lipid solubility of testoster-
one and sustains its residence time. Following administration,
the esters are released from the intramuscular site and stored
in fat depots where they are cleaved to the parent compound.
In general, the release rate decreases with the length of the
chain and with increasing lipophilicity.
Testosterone enanthate (Androtardyl\) (Fig. 5) is one of
the most common testosterone derivatives used. This sub-
stance has a terminal half-life of 4.5 days; maximum concen-
trations are reached after 10 h following a single injection of
250 mg. Multiple-dose pharmacokinetics revealed an optimal
injection interval of 2Y3 weeks at this dose (27) (Fig. 6).
Mackey et al. (32) evaluated the tolerability of deep
intramuscular injections of testosterone enanthate in a castor
oil vehicle over a period of 8 months. They concluded that
deep intramuscular injection was generally safe but caused
relatively frequent minor side effects, including pain and
bleeding.
Testosterone cypionate (Depo-Testosterone\) (Fig. 5)
has similar pharmacokinetics to testosterone enanthate. As
such, the cypionate does not provide any clear advantage
over the enanthate ester. The recommended dose for
testosterone cypionate is 200 mg every 2 weeks (33).
Testosterone propionate (Testex\) (Fig. 5) has to be
given every few days to achieve physiological testosterone
levels. This ester has a terminal half-life of only 19 h; after a
single injection of 50 mg, the maximum concentration was
reached after 14 h. It is obvious that this substance requires
more frequent injections: multiple-dose pharmacokinetics
reveals optimal intervals of 2Y3 days (27). Because of its
pharmacokinetics, the propionate is not suitable for long-
term treatment of hypogonadism.Fig. 4. Testosterone undecanoate.
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Intramuscular therapy, although the most widely used
delivery route, is not well accepted by patients. Because of the
limited potency of testosterone and the low solubility of these
testosterone esters, large amounts are required in a large
volume (about 4Y8 mL intramuscularly, depending on the
vehicle). Moreover, in some patients, injections may be
associated with local pain, bleeding, or bruising and with
allergic reactions to sesame oil, the injection vehicle for
testosterone enanthate, or to cottonseed oil, the vehicle for
testosterone cypionate (34). Although self-administration is
possible, most patients need the help of health care profes-
sionals for treatment, a requirement that is expensive and
inconvenient.
These testosterone esters are quite effective in producing
and maintaining normal virilization but have a number of
undesirable features, such as the widely fluctuating serum
testosterone levels (supraphysiological levels immediately
after injection and subtherapeutic levels 10 Y14 days later)
and the need for frequent injections (26,35). A smoother
profile could be obtained by using smaller doses more
regularly, but increasing the frequency of injections is often
unacceptable for patients. As a result, patients may experi-
ence side effects resulting from the supraphysiological
testosterone plasma levels during the first few days after
injection, such as mood disturbances and unfavorable
changes in hematocrit and plasma lipid profile. Moreover,
toward the end of the administration interval, plasma
testosterone levels often drop below the normal range, which
may result in the recurrence of hypogonadal symptoms (26).
Combinations of short- and long-acting esters are avail-
able to provide better pharmacokinetic profiles (e.g., Sus-
tanon\ 250: testosterone propionate 30 mg, testosterone
phenylpropionate 60 mg, testosterone isocaproate 60 mg, and
testosterone decanoate 100 mg). In practice, however, the
wide variation in testosterone levels still persists with these
preparations. For treatment of male hypogonadism, there
seems to be no advantage over the single-drug preparations
(27).
Fig. 5. Testosterone esters used in intramuscular therapy: (A) enanthate; (B) cypionate; (C) propionate.
Fig. 6. Extrapolated serum testosterone concentrations after intramuscular injection of testosterone enanthate 250 mg in men with
hypogonadism: (a) every week; (b) 2 weeks; (c) 3 weeks; (d) 4 weeks (27).
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Subcutaneous Implants
Testosterone pellet implantation was one of the first
modalities employed for clinical use and dates back to 1937.
Traditional implants are defined as small sterile tablets
consisting of the highly purified drug, usually compressed
without excipients, and intended for subcutaneous insertion.
The device has a high degree of hardness and virtually zero
porosity. Because water does not penetrate the matrix, drug
release occurs principally by surface dissolution. As a result
of the inherently poor solubility of steroid drugs, this method
provides an ideal form for depot medication (36). Oerton\
pellets containing testosterone and marketed by Schering are
one example of this technology.
Pellets/rods (Testopel pellets\) can be produced by high-
temperature molding and are available in two sizes, containing
100 or 200 mg of crystalline steroid, with a length of 6 or 12 mm
and a diameter of 4.5 mm. Implanted subcutaneously every
4Y6 months (37), under sterile conditions, they remain under
the skin of the lower abdominal wall; other possible sites are
upper thigh, deltoid, or gluteal muscle (38). Absorption
occurs via erosion from the pellet surface following zero-order
kinetics. A comparison between intramuscular injections of
250 mg mixed testosterone esters at two weekly intervals, oral
testosterone undecanoate (120 mg/day) and subcutaneous
pellets (6  100 mg) in a prospective, randomized, crossover
design indicated a constant elevation of testosterone in the
pellet-treated patients that lasted for 4 months, whereas
marked fluctuations were seen in the injection group (39).
Subdermal testosterone implants produced a similar pattern
to that obtained from intramuscular testosterone, but the
profile of high initial peaks and decline thereafter extended
over a much longer period of up to 6 months. Because of the
longer time span, the patient hardly notices the slow swings
of serum testosterone. Moreover, as surgical insertion is
required only two to four times per year, patient acceptance
is high.
Depot formulations of testosterone do suffer, however,
from administration difficulties, as a minor surgical procedure
is required. The possibility of extrusion, although rare, also
exists (40). A review of 13 years of experience in subdermal
testosterone implantation in 221 men showed limited adverse
local effects (11% of total 973 consecutive implants) such as
extrusion, bleeding, and inflammations/infections. Effects
were related to work activity and occurred more often in
thinner men. Palpable subdermal fibrosis is infrequent (41).
Transdermal Delivery
Transdermal testosterone offers advantages over oral
and intramuscular application in that both the first-pass
metabolism in the liver after oral administration, requiring
high testosterone doses, and potentially painful injections
combined with supraphysiological testosterone serum con-
centrations are avoided. Moreover, the endogenous, circadi-
an rhythm of testosterone secretion can be mimicked.
Testosterone is a good candidate for transdermal delivery
(3). Steroids are hydrophobic, relatively small molecules, and
highly potent (42). According to the literature (43,44), the
permeability of testosterone through human skin falls
between 4.0  10j4 and 2.2  10j3 cm/h.
Previous experience with E2 patches has shown that the
amount delivered to the blood stream by the transdermal
system is small because the daily dose required is small.
However, because a healthy adult male produces 3Y11 mg of
testosterone per day, a high efficiency delivery system is
needed to administer this steroid in an amount that is 50Y100
times the amount of E2 delivered via the skin (45). With the
use of permeation enhancers, transdermal administration of
testosterone at this level is possible. Numerous studies evalu-
ated the percutaneous flux of testosterone using various
enhancers such as liquid petrolatum, propylene glycol dipe-
largonate, Labrafac\, Labrasol\ (mixture of mono-, di-, and
triglycerides and mono- and difatty esters of polyethylene
glycol) (46), 1-[2-(decylthio)ethyl]azacyclopentan-2-one
(HPE-101) (47), or menthol (48).
The earlier topical androgen formulations (ointments),
although convenient, carry the risk of transmission from one
person to another, resulting in the androgenization of female
partners (49). Percutacrine Androgenique Forte\, formerly
commercialized by Besins-Iovesco (Paris, France) was a
topical ointment containing 10 mg/mL of testosterone. The
low transcutaneous flux of testosterone from this formulation
required the use of percutaneous enhancers: ether, alcohol,
propylene glycol, and eucalyptus oil. It was administered by
30 drops daily on the abdomen (50). These solvents permeate
skin, but without rate control and defined area of application,
and could lead to excessive amounts of the drug in plasma.
These problems have led to the design of fixed-area, easily
applied, adhesive systems that control the rate and duration
of testosterone input.
Because there are special principles to be followed in
testosterone substitution in older men, such as a preference
for the natural substance, reequilibration of physiological
hormone levels, and the opportunity to stop treatment
immediately as a result of possible development of prostatic
disease), transdermal application represents an advantageous
treatment modality for this age group (27) (Table II).
Scrotal Testosterone Patch (Testoderm\VAlza Pharma-
ceuticals, Mountain View, CA, USA). Testoderm\ was the
first testosterone transdermal therapeutic system (TTS)
(51Y53) introduced in 1995 and available in two sizes, 40
and 60 cm2. The patch is applied on the scrotum and delivers
4 or 6 mg of testosterone, respectively, over a 24-h period. This
polymer matrix-type patch containing 10 or 15 mg natural
testosterone is composed of two layers: one is a soft, flexible,
clothlike backing of polyethylene terephthalate; the other lay-
er is a testosterone-containing film of ethyleneYvinyl acetate
(EVA) copolymer that gently adheres, at body temperature,
to the scrotal skin surface without the need for a specific
adhesive and modulates the permeation of testosterone.
In matrix systems, the solute is uniformly dispersed into
an appropriate vehicle, usually a high-viscosity polymer. Such
systems are easy and cheap to formulate, and they prolong the
period of drug delivery. However, in most cases, the rate of
drug release declines as a function of time. Although this may
be disadvantageous when constant delivery is desired, the
plasma profile thus produced may match with the body’s
natural rhythm for substances such as hormones. The matrix
system for testosterone takesadvantage of this behavior and
delivers testosterone in a circadian pattern; serum tes-
tosterone levels increase, then slowly decrease over 24 h. The
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patch is rather thin (0.14 mm) and is applied each morning to
the shaven scrotum where steroid absorption is highest
(approximately 40 times that in the forearm) (54) and worn
for 22Y24 h. The TTS delivers approximately 40% of its total
testosterone content.
An initial pharmacokinetic study with this patch was
performed by Findlay et al. (55). Testosterone levels rose
within l h of application, peaked in 2Y3 h, and gradually
declined over 22 h. Levels decreased more abruptly during
the last 2 h after the patch was removed. The nadir, seen at
22 h of application, was 60Y80% of the peak value seen at
2Y3 h (Fig. 7). This profile mimics the diurnal testosterone
fluctuation in healthy men. The mean average testosterone
concentration 22 h after application in this study was 135 T
38 ng/dL with placebo and 348 T 66, 455 T 77, and 624 T
65 ng/dL with the 5-, 10-, and 15-mg patches, respectively.
Numerous studies have shown the beneficial effects of
Testoderm\ on bone density (18,56), energy and sexual func-
tion, fat mass, and lean body mass (15,57). Moreover, Tes-
toderm\ did not influence lipid profiles (58) contrary to that
seen with more conventional administration of testosterone
(59). No adverse effects on the prostate have been observed.
Skin irritation is rare, and allergic contact dermatitis has not
been seen (60).
After application of scrotal testosterone patches, su-
praphysiological dihydrotestosterone serum levels were
measured (61) because of the presence of the enzyme 5a-
reductase in scrotal skin. Long-term side effects of high doses
of DHT are unknown, but increased DHT concentrations
have been measured in men with benign prostate hyperpla-
sia. However, whether increased DHT concentrations are a
cause of this hyperplasia or a consequence thereof is not yet
resolved.
Although Testoderm\ is preferred to intramuscular
therapy, the fact that it is necessary to shave the scrotum to
obtain good adhesion limits its acceptability. Moreover,
these patches are not practical when the scrotal surface is
inadequate.
Testoderm TTS for application to nonscrotal skin has
also been marketed. The system comprises four layers: a
flexible backing of transparent polyester/EVA copolymer
film, a drug reservoir of testosterone in alcohol gelled with
hydroxypropyl cellulose, an EVA copolymer membrane
coated with a polyisobutylene adhesive formulation, and a
protective liner of silicone-coated polyester which must be
removed before application. The single patch delivers 5 mg of
testosterone per day. The incidence of itching at the applica-
tion site was 12%, and 3% of users experienced erythema. To
Table II. Transdermal Testosterone Replacement Options: Advantages, Disadvantages, and Doses Available
Formulation Tradename Testosterone dose (mg/day) Advantages Disadvantages
Gel
Hydroalcoholic
preparation
Androgel\, Testim\ 5 or 10, delivery efficiency:
10Y30%
No injections Expensive
Reliable delivery Potential of testosterone
transfer to female
partner
No visible patch
Gel dries quickly
Good clinical response
Mimics circadian variation
Scrotal patch
Drug-in-adhesive matrix
Testoderm\ 4 or 6, delivery efficiency:
40%
No injections Requires adequate scrotal
area and shaving
of scrotum
Active surface
area: 40 cm2
Good clinical response
May cause irritation
Total surface
area: 40 cm2
Mimics circadian variation
Adhesion problems
Increased DHT levels
Nonscrotal patch
Liquid reservoir system Androderm\ 5 or 10, delivery efficiency:
20%
No injections High incidence of local
skin reactionsNo need to shave
scrotal area
Active surface
area: 7.5 cm2
Good clinical responseTotal surface
area: 33.2 cm2 Mimics circadian variation
Normal serum levels of
dihydrotestosterone
DHT = dehydrotestosterone.
Fig. 7. Serum testosterone concentrations in five men with hypo-
gonadism using a 10-mg scrotal patch (mean T SEM) (60).
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date, however, this patch has suffered from adhesion prob-
lems, which have significantly limited its use (62,63).
Nonscrotal Testosterone Patch (Androderm\VWatson
Pharma, Corona, CA, USA). The Androderm\ testosterone
transdermal delivery system was the first nonscrotal patch
developed for physiological replacement therapy in hypogona-
dal men (3). This system was designed to overcome the pitfalls
of the scrotal system. Introduced in 1996 in the United States,
this testosterone transdermal system is available as a 37- or
74-cm2 patch that delivers 2.5 or 5 mg of testosterone per day
(64). This patch comprises a liquid drug reservoir containing
testosterone in a permeation-enhancing vehicle composed of
water, ethyl alcohol, glycerin, glycerol monooleate, methyl
laurate, and gelling agents, separated from the skin by a
microporous membrane and surrounded by a peripheral
adhesive system which affixes the system to the skin (2,65).
Androderm\ is designed to be applied everyday in the
evening (between 8:00 p.m. and midnight) (66), rotating
between skin sites on the back, abdomen, upper arms, and
thighs. Its delivery efficiency is around 16%. Most patients
require two 2.5-mg patches or one 5-mg patch, which are
bioequivalent (67) and provide physiological testosterone
levels in over 90% of treated men (68). As 60% of the
testosterone is delivered in the first 12 h, the patches
approximate the normal circadian rhythm of testosterone
when applied at night (69) (Fig. 8). When two 2.5-mg patches
were applied for 24 h, 60% of the drug was delivered in the
first 12 h and 40% in the second 12-h period. There was no
accumulation of testosterone during continuous therapy.
After system removal, serum testosterone levels decreased
with a half-life of 70 min and returned to the hypogonadal
range within 24 h.
In addition, nonscrotal systems do not result in
increased dihydrotestosterone levels seen with Testoderm\
(70). The DHT/testosterone and E2/testosterone ratios after
Androderm\ application were 1:10 and 1:200, respectively,
values comparable with those found in eugonadal men.
Overall, with the nonscrotal patch, effects on sexual
function and prostate volume seemed to match those
achieved following conventional injection therapy (71).
Improvements in sexual function, libido, energy level,
mood, and lean body mass have been reported (72). Mean
serum prostate-specific antigen levels and mean prostate
volume remained within the normal range. Safety assess-
ments have disclosed no clinically significant changes in lipid
measures or serum chemistry.
In parallel with the development of testosterone trans-
dermal systems, a number of conditions, in both males and
females, where testosterone production is diminished and
replacement therapy may be beneficial, have been investi-
gated (73). For example, Androderm\ has been evaluated for
the treatment of adolescent hypogonadal males with b-
thalassemia (74) and has been shown to induce increases in
height and body weight. Genital development and an
increased bone mineral density were also observed. To attain
physiologic levels of serum testosterone in hypogonadal
adolescent males, De Sanctis et al. (74) proposed modified
application regimens of Androderm\. For the treatment of
14Y16 year-olds, a single 2.5-mg patch should be applied at
night and removed 12 h later, in the morning. For the 17Y19
year-olds, a single 2.5-mg patch is applied nightly for 24 h.
Local skin reactions are the most common adverse
events reported for the nonscrotal testosterone transdermal
system, with approximately 50% of men who participated in
clinical trials reporting transient, mild to moderate erythema
at the application site. Burnlike blister reactions occurred in
12% of men during the clinical trials, typically only once at a
single application site (75). It seems that the permeation
enhancers are responsible for this adverse reaction. Most
reactions were associated with application of the systems
over bony prominences or on parts of the body that could
have been subject to prolonged pressure during sleep or
sitting. Pretreatment of the application site with 0.1%
triamcinolone acetonide cream decreased the skin reactions.
However, despite the use of steroid, the significant skin
reactions occurring in about one third of recipients lead to a
high discontinuation rate (10Y15%) (76,77).
Testosterone Gels. The skin is nevertheless an attrac-
tive route for testosterone delivery, despite the drawbacks of
the transdermal patches such as dose inflexibility, visibility,
and skin irritation. Transdermal testosterone gel prepara-
tions have recently become available. Their performance is
similar to that of the transdermal patches but with a much
lower incidence of skin reactions.
Androgel\ (Solvay Pharmaceuticals, Marietta, GA,
USA) is a 1% hydroalcoholic gel formulation. After a 10-g
application, at a single site (left arm/shoulders) or at four
different separate sites (left and right arms/shoulders and left
and right abdomen), the gel dried in less than 5 min, and the
stratum corneum served as a reservoir for the subsequent re-
lease of testosterone over several hours (78). The mean serum
levels rose 2- to 3-fold above baseline at 0.5 h and 4- to 5-fold
Fig. 9. Serum testosterone concentrations (mean T SEM) over
24 h after an initial application of 100 mg of steroid in a 1% gel (78).
Fig. 8. Serum testosterone concentrations in hypogonadal men using
a 5-mg nonscrotal testosterone patch (mean T SEM) (69).
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after 24 h of application (reaching steady state) (Fig. 9).
The testosterone concentration remained stable at 4- to
6.5-fold above baseline levels and returned to the pretreat-
ment value 4 days after cessation of the treatment. About
9Y14% of testosterone in the gel was bioavailable, and the
serum dihydrotestosterone/testosterone ratio was normal.
Although no patients reported any major skin reaction
in the initial pharmacokinetic study, with chronic treatment,
about 5% manifested mild irritation (79). This gel has been
shown to improve muscle strength, lean body mass, sexual
function, mood, and bone mineral density (80).
In early 2003, a new testosterone gel, Testim\ (Auxilium
Pharmaceuticals, Malvern, PA, USA) was launched in the
United States. This 1% hydroalcoholic formulation utilizes
the permeation enhancer cyclopentadecanolide. A recent
study found that hypogonadal patients treated with Testim\
absorbed 30% more testosterone than those treated with
Androgel\ (81,82).
A major problem with conventional topical formula-
tions is that the pharmacokinetics and pharmacodynamics
are not reliably predictable because of poor control of the
drug amount applied and of the area of application and
because of the inter- and intraindividual variations in skin
permeability. Moreover, topical androgen formulations are
applied over large surface areas, and although there is little
residue left on the skin, there remains a chance of person-to-
person transmission via skin contact immediately after
application (83). In a phase I study, Rolf et al. (84,85)
studied the pharmacokinetics of two doses of a transdermal
hydroalcoholic gel containing 2.5% testosterone in gonado-
tropin-suppressed normal men. Physiological serum concen-
trations of testosterone were restored during the 10-day
treatment period in the group of men applying 5 g tes-
tosterone gel. A physiological circadian profile was attained.
E2 and DHT concentrations did not exceed normal values.
Washing 10 min after gel application did not influence the
absorption of testosterone and significantly reduced the
risk of contamination of female partners or infants. In
contrast, to achieve good absorption of testosterone follow-
ing Androgel\ treatment, patients are instructed not to wash
the skin for 5Y6 h, and contamination has been observed in
women after skin contact with men who had applied this
formulation several hours earlier.
Summary
Various androgen replacement therapies for male hypo-
gonadism are available (Table III). The choice of androgen
preparation seems to be mainly determined by patient
preference, with men opting for the mode of administration
that delivers treatment in the most convenient way with
minimum side effects. Until recently, intramuscular depot
injections offered the most satisfactory combination of safety
and efficacy, despite the fluctuations in serum testosterone
levels that cause changes in sexual function, energy, and mood.
On the other hand, because of limited effectiveness and a poor
safety profile, currently available oral androgens are not
recommended. The scrotal patch delivers testosterone at a
controlled rate but has been associated with elevated levels of
DHT and altered DHT/testosterone ratios. The nonscrotal
transdermal delivery system achieves normal diurnal levels of
testosterone, normal levels of DHT and E2, and normal ratios
of DHT/testosterone and E2/testosterone. Local skin reac-
tions are the most common adverse effect. These drawbacks
can be avoided with gels that offer the same pharmacokinetic
profile as the patches but carry the risk of transfer of
testosterone to a partner. Nevertheless, transdermal delivery
allows patients to self-administer their medication and to
select among several anatomical sites for administration. For
these reasons, this route of testosterone delivery represents a
useful step toward ideal androgen replacement therapy.
Table III. Testosterone Dosage Forms
Route Drug Dosage form Dose
Stage of
development
Oral Testosterone undecanoate Capsules 40 mg, 2Y4/day On market
17!-Alkylated androgens
(methyltestosterone and
fluoxymesterone)
Tablets 10Y50 mg/day On market
Testosterone cyclodextrins Tablets 7.5Y15 mg/day Clinical trials
Buccal Testosterone Bioadhesive tablet 30 mg, 2/day On market
Intramuscular Testosterone enanthate Oily suspension 200Y250 mg every
2Y3 weeks
On market
Testosterone cypionate 200 mg every 2 weeks On market
Testosterone propionate 50 mg every 2Y3 days On market
Testosterone undecanoate Aqueous suspension 200Y600 mg every
2Y3 months
Clinical trials
Testosterone buciclate
Testosterone microspheres 615 mg every
2Y3 months
Clinical trials
Subcutaneous Testosterone Pellets 3Y6 (200 mg) every
6 months
On market
Transdermal Testosterone Gel 1%, 10 g/day On market
Scrotal patch 10/15 mg, 1/day On market
Nonscrotal patch 2.5/5 mg, 2  2.5 or
1  5/day
On market
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STATUS OF RESEARCH
AND DEVELOPMENT PROJECTS
Today, oral, parenteral, implantable, and transdermal
testosterone dosage forms are available for clinical use, and
others are under development. Each route of administration
produces a distinct pharmacokinetic profile, the biological
significance of which is not fully appreciated. Recently, a
variety of additional methods for testosterone administration,
including intramuscular therapy (86), nasal and pulmonary
delivery, sublingual tablets (87), and topical aerosols (88,89),
have been investigated in an attempt to overcome some
perceived drawbacks with existing approaches.
Parenteral Delivery
A major disadvantage of existing parenteral prepara-
tions is the wide interinjection fluctuations in the resulting
testosterone levels. Both testosterone undecanoate (90) and
testosterone buciclate (600 mg suspended in aqueous solu-
tion) (91) (Fig. 10) are currently undergoing evaluation and
seem to offer longer-acting formulations and less variation in
testosterone concentration.
Whereas already used orally, testosterone undecanoate
revealed a significantly longer half-life compared with
testosterone enanthate (92). This 17b-hydroxyl ester in castor
oil (250 mg/mL) had t1/2 = 20.9 T 6.0 days, with a maximal
concentration of 19.3 T 2.1 nmol/L after 11.4 T 1.5 days (93).
Fig. 10. Serum concentrations (mean T SEM) of androgens [sum of
testosterone and dehydrotestosterone (DHT)] (upper panel), testos-
terone increase over baseline (middle panel), and DHT (lower panel)
after single-dose intramuscular injections of 200 mg (open triangles)
or 600 mg (filled circles) of testosterone buciclate to hypogonadal
men. Broken line in the upper panel indicates the normal upper limit
for DHT (91). After injection of 600 mg, androgens increased
significantly and were maintained in the lower normal range for up
to 12 weeks, with a Cmax = 13.1 T 0.9 nmol/L at Tmax = 6 weeks.
Fig. 11. Serum total (upper panel) and free testosterone (lower
panel) levels before and after testosterone microcapsule administra-
tion in man (mean T SEM, n = 10) (96).
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The optimal injection interval was set between 6 and 8 weeks,
but it seems that the intervals may even be extended to 12
weeks. Likewise, another ester, testosterone buciclate,
showed a rather favorable pharmacokinetic profile (94).
Further clinical studies showed a maximum concentration 9
weeks postinjection of 13.1 T 1.8 nmol/L, the half-life being
about 30 days. An injection of 1000 mg testosterone buciclate
maintained testosterone serum levels within the normal
range up to week 16 (95).
Another way to control the absorption kinetics of
testosterone involves microencapsulation. In this context,
efforts have been underway to develop a long-acting depot
formulation based on polylactideYpolyglycolide micropar-
ticles. Testosterone (315 mg) has been encapsulated in a
matrix (Medisorb 85:15 lactide/glycolide copolymer) that
biodegrades over about 150 days (96) (Fig. 11). The micro-
capsules provide reasonably uniform eugonadal levels of
serum testosterone for 10Y11 weeks in hypogonadal men,
releasing 3 mg of testosterone per day after a deep intramus-
cular injection, with approximately zero-order kinetics. No
adverse local reactions, apart from pain at the site of injection,
were noted. Whereas this formulation represents an attractive
alternative to existing methods of androgen replacement, it is
limited by the relatively large volume of diluent needed to
inject the microcapsules and by the fact that the diurnal
rhythm of serum testosterone secretion is not produced (97).
Nasal Delivery
In man, the area of the nasal mucosa is approximately
150 cm2, and there is a dense network of blood vessels
offering the potential for efficient drug absorption while
avoiding first-pass metabolism.
In an early study, a relatively simple nasal formulation of
testosterone (methyl cellulose in distilled water) was tested in
man. A very rapid and significant increase in plasma testos-
terone was observed (Tmax = 20 min), which returned to
baseline after 120 Y180 min (98). This pharmacokinetic profile
is comparable to that following oral administration of testos-
terone undecanoate; however, the duration of action is quite
short, which means that repeated dosing would be necessary.
In addition, testosterone is poorly soluble in water (0.01 mg/
mL), and an aqueous solution containing sufficient drug
(3 mg) for human use is not feasible. Solubilizers commonly
induce damage to the nasal mucosa; thus, their use is not
recommended. It follows that nasal delivery of testosterone is
unsuitable for long-term therapy and has not been pursued.
Further work, such as that of Hussain et al. (99), has
therefore focused on the potential of the nasal route using a
water-soluble prodrug, testosterone 17b-N,N-dimethylgly-
cinate hydrochloride. The aqueous solubility of this derivative
is more than 100 mg/mL. The prodrug was almost immediately
absorbed from the rat nasal cavity. The apparent half-life of
prodrug disappearance is 10 Y20 min, and the peak plasma
concentration of testosterone was attained within 12Y20 min
(Fig. 12). The availability of the prodrug and testosterone was
similar to those achieved after intravenous administration.
Therefore, this prodrug could allow an aqueous formulation of
testosterone well tolerated by the nasal cavity.
Increased absorption of testosterone is possible on
solubilization of the drug and/or prolongation of the formu-
lation residence time in the nasal cavity. Ko et al. (100)
achieved this objective using a new emulsion formulation
containing Span 80 and neutralized soybean oil dispersed in
phthalate buffer with Tween 80. A dose of approximately 3.8
mg per rabbit was administered via a spray formulation.
Electrostatic interactions between the emulsion droplets and
the nasal mucosa prolonged the contact of drug with the
membrane, enhancing drug absorption with a bioavailability
of over 50% and Tmax = 20 min.
Pulmonary Delivery
Local and systemic inhalation therapies can benefit from
the controlled release of therapeutic agent, as might be
achieved using biodegradable polymers. Slow release from an
inhaled therapeutic particle can prolong the residence of an
administered drug in the airways and can control the rate of
the compound’s appearance in the bloodstream. Pulmonary
delivery also avoids first-pass metabolism by the liver, and
this can improve patient compliance because dosing frequen-
cy is reduced. However, an effective, slow-release inhalation
therapy requires that the lungs’ natural clearance mechanism
be suspended or avoided.
Recently, a new type of inhalation aerosol, characterized
by particles of small mass density and large size [porous
particles composed of 50:50 poly(lactic acid-co-glycolic acid,
PLGA], has permitted the highly efficient delivery of
testosterone in rats. Particles with mass densities less than
0.4 g/cm3 and mean diameters exceeding 20 mm were inspired
deep into the lungs and escaped the lungs’ natural clearance
mechanisms. The systemic bioavailability was approximately
ten times that from conventional inhaled particles (smaller,
porous PLGA particles). Blood levels of testosterone
remained above background levels for 12Y24 h, confirming
the slow release mechanism (the testosterone systemic t1/2
being 10Y20 min). Testosterone bioavailability relative to
subcutaneous injection was nearly doubled (101).
Aradigm’s pulmonary technology provides aerosol gen-
eration and deep-lung dosing, suitable for either the rapid
Fig. 12. Plasma concentrations of testosterone 17b-N,N-dimethylgly-
cinate hydrochloride (&) and testosterone (r) after nasal adminis-
tration of the prodrug at a dose equivalent to 25 mg/kg of
testosterone in rat (mean T SEM, n = 3) (99).
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transfer of molecules into the bloodstream or localized
delivery within the lung. The central element of their system
is the AERx\ Strip dosage form, which contains a disposable
nozzle to insure superior aerosol performance each and every
time the patient inhales medication. The devices utilizes a
piston mechanism to expel the formulation from the dosage
form. In a recent study, Davison et al. (102) determined the
pharmacokinetics and safety of a single dose of orally inhaled
testosterone via the AERx\ System in 12 postmenopausal
women stabilized on oral estrogen. Each patient inhaled a
single dose of testosterone (100, 200, or 300 mg). The AERx\
System delivered aerosolized testosterone and achieved a
pulse kinetic profile (Tmax = 1.4 T 0.5 min at the maximal
dose of 300 mg) with a rapid return to pretreatment levels,
mimicking physiological hormonal secretion.
Buccal Delivery
Using bioadhesive tablets, testosterone, testosterone
acetate, and testosterone propionate were better absorbed
(p < 0.05) than less water-soluble esters. The mean absolute
bioavailability of testosterone from the bioadhesive tablet
was 14.1%. Buccal administration results in plasma levels
above 37 ng/mL for 15Y24 h (103).
A novel bilayer mucoadhesive waxYfilm composite has
been developed (104) containing Eudragit\ and polycarbo-
phil. In rabbits, the tested disk containing 4 mg of testosterone
and sodium lauryl sulfate as an enhancer produced zero-order
release, with a Tmax = 200 T 35 min and a bioavailability of
50.2%. Similar results were obtained in hypogonadal men
receiving one 10-mg buccal testosterone tablet per day. The
delivery pattern was pulsatile, with a maximal testosterone
concentration 30 min postadministration and a return to
baseline in 4 Y 6 h. Supraphysiological levels of testosterone
were observed but lasted for only 1.5Y4 h after the first
administration. Accumulation of testosterone did not occur,
even over 8 weeks of treatment (105) (Fig. 13).
Baisley et al. (106) determined the mean serum testos-
terone, free testosterone, and dihydrotestosterone concen-
trations showing circadian variation over 24 h following
three doses of buccal-adhesive testosterone tablets (10, 20, or
30 mg) given daily over 10 days in healthy men. Peak testoster-
one concentrations were reached 8Y9 h after dosing, and steady
state was attained by day 5. The average 24-h concentrations for
the three doses were within the normal range for eugonadal
men, and the buccal tablets were well tolerated.
Transdermal Delivery
The transdermal route is unique insofar that it can
provide physiological replacement of testosterone that
mimics the serum level, circadian pattern, and metabolism
observed in healthy young men, adolescent males, and
premenopausal women. The new applications of the trans-
dermal route involve amelioration of existing delivery
systems (patches, gels) and the development of new
approaches based on aerosols and sonophoresis.
Patches
It has been reported that ethanol/water (70:30) is the
best cosolvent combination for transdermal testosterone
delivery (107). A reservoir-type delivery system containing
1% (w/v) dodecylamine as a skin permeation enhancer has
been developed and allowed the testosterone permeation
rate to be increased from 2.7 to 48 mg cmj2 hj1. This patch
was formulated using an EVA membrane coated with a pres-
sure-sensitive adhesive and showed comparable plasma con-
centration profiles in vivo when compared with Androderm\
in rats (108).
Hydrogel
In a phase I study (84,85), the pharmacokinetics of two
doses of a transdermal hydroalcoholic gel containing 2.5%
testosterone has been evaluated in gonadotropin-suppressed
men. Physiological serum concentrations of testosterone
were restored during the 10-day treatment period in the
group applying 5.0-g testosterone gel. A physiological
circadian profile was attained. E2 and DHT concentrations
did not exceed normal values. Washing 10 min after gel
application did not influence the resorption of testosterone
Fig. 13. Pharmacokinetics of mean (SD) total testosterone after administration of testosterone (Ì) or placebo ()) buccal tablets (105).
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and would presumably reduce the risk of contamination of
female partners or infants. For comparison, to achieve good
uptake of testosterone during Androgel\ application,
patients are instructed not to wash the skin for 5Y 6 h, and
contamination has been observed in women after skin
contact with men who had applied Androgel\ several hours
earlier.
Recently (109), a polyvinyl alcohol and polyisobutylene-
based soft hydrogel formulation has also been developed.
This gel, which again used dodecylamine as an enhancer,
formed a thin film on the skin 2Y3 min after application and
remained in a dried-film form for at least 24 h.
Sepa\ (ethylene glycol condensed with decyl aldehyde) is
a patented absorption enhancer (110). Sepa\ is an acronym
for ‘‘soft enhancement of percutaneous absorption,’’ where
soft refers to the reversibility of the skin effect. The
permeation of testosterone from a gel containing this
enhancer, Opterone\ (1% testosterone + 5% Sepa), has
been evaluated. Application of 2.5 g of the gel resulted in the
same area under the curve (AUC) as those achieved after
administration of 5 g of Androgel\. According to the
company which has developed Opterone\ (Macrochem
Corp., Lexington, MA, USA), the gel differs from currently
marketed products in that it needs to be applied to a
significantly smaller surface area to achieve the same
absorption, a property that is also expected to reduce the
risk of transfer to children and partners (111).
Metered Dose Transdermal Spray
A metered dose transdermal system (MDTS\) (Fig. 14)
has been developed by Acrux, Ltd., West Melbourne,
Australia. MDTS\ technology has the potential to overcome
some of the limitations with existing transdermal drug
delivery systems, e.g., the irritation and adhesion problems
associated with transdermal patches. The solution is formu-
lated such that a volatile component evaporates, leaving a
concentrated solution of drug in a vehicle that is rapidly
taken up into the outer layers of the skin. Drug is then
released from this reservoir in the skin over a prolonged
period.
The liquid formulations used in the MDTS\ system
incorporate the generally recognized as safe (GRAS) status
skin penetration enhancers, octyl salicylate and padimate O,
which have been used for many years as sunscreen agents.
This technology has also been used for other drugs, such as
E2 (112) and granisetron (113), as well as testosterone (88).
Rapid partitioning of testosterone and padimate O into swine
skin occurred after 1 min, with 70 and 60% of the applied
dose (testosterone = 12% w/v; padimate O = 8% v/v) re-
maining in the skin after the unabsorbed formulation was
removed by rinsing with absolute ethanol. The cumulative
amount of testosterone at 24 h penetrating across snake skin
was significantly enhanced by up to 6-fold for octyl salicylate,
by 3-fold for oleic acid and Azone, and by 2-fold for
padimate O compared with control sample. A testosterone
MDTS\ is being evaluated clinically for the treatment of
female androgen insufficiency (Fig. 15).
Ultrasound-Enhanced Transdermal Transport
The application of low-frequency (20Y100 kHz) ultra-
sound can significantly enhance the transdermal transport of
drugs (114). This technique, used originally in physiotherapy
and sports medicine, has now been extended to transdermal
drug delivery and glucose monitoring (115Y117).
It seems that ultrasound, via a mechanism based on
cavitation (118), is able to significantly permeabilize the skin.
The duration of exposure can be quite short, with an effect
lasting up to more than 12 h. Preliminary studies have shown
that ultrasound can permit improved testosterone delivery
across the skin (44).
CONCLUSION
Testosterone deficiency is associated with adverse effects
on body composition, bone density, sexual function, and mood
and may also increase cardiovascular risk. Numerous studies
have demonstrated the benefits of testosterone replacement in
overtly hypogonadal men. There are several possible admin-
istration routes for testosterone replacement. Each approach
has advantages and drawbacks, and the choice of the method
of replacement will often be determined by patient prefer-
ence. Although new developments are promising, it seems
that, among the available treatments, only transdermal
delivery has provided pharmacokinetic behavior that most
closely mimics the natural diurnal variations in man.
Fig. 15. Mean serum testosterone concentration after a testosterone
MDTS\ application in women (Acrux, Inc.).
Fig. 14. MDTS\ applicator (Acrux, Inc.).
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